AOD-9604: fat-burning growth hormone fragment

What this is

AOD-9604 is a synthetic 16-residue peptide fragment derived from the C-terminal region of human growth hormone, with an N-terminal tyrosine residue added for manufacturing stability. It was designed in the late 1990s at Monash University, Australia, by a team including Frank Ng and Michael Heffernan, to isolate growth hormone's fat-mobilizing activity while removing the growth-promoting, IGF-1-raising, and insulin-desensitizing effects of full-length GH therapy. The compound was licensed to the Australian biotechnology company Metabolic Pharmaceuticals and taken into a full pharmaceutical clinical program. It is not approved as a drug anywhere. The stored sequence (YLRIVQCRSVEGSCGF) is the linear backbone; the two cysteine residues (C7 and C14) form a disulfide bond in the active peptide, giving the molecule a cyclic topology — this structural feature is not visible from the raw sequence alone.

History

AOD-9604 was developed through the late 1990s and 2000s at Monash University and Metabolic Pharmaceuticals, with foundational metabolic characterization published by Ng and colleagues (Hormone Research, 2000) and Heffernan and colleagues (Endocrinology, 2001). The design premise was that the C-terminal fragment of human growth hormone — residues 177–191 with an added N-terminal tyrosine — contained the lipolytic domain responsible for GH's fat-mobilizing properties, while the growth-promoting and metabolic-destabilizing effects resided elsewhere in the molecule. Metabolic Pharmaceuticals advanced the compound through Phase I safety studies, a Phase IIa dose-finding and tolerability study (METAOD004, published by Stier and colleagues, Journal of Endocrinology and Metabolism, 2013), and ultimately a Phase IIb obesity efficacy trial. The Phase IIb trial — the most rigorously powered human test of the compound — did not meet its primary weight-loss endpoint, and the obesity drug program was discontinued, with results reported only in Australian Stock Exchange (ASX) corporate disclosures rather than peer-reviewed literature. The compound was subsequently repositioned toward osteoarthritis and cartilage repair applications and obtained FDA GRAS (Generally Recognized as Safe) status as a food ingredient. It entered the research-chemical and wellness markets primarily on the original "fat-burning fragment" marketing premise, a framing directly contradicted by the Phase IIb data.

What it does

AOD-9604 acts selectively on fat cells to promote fat breakdown (lipolysis) and suppress fat formation (lipogenesis), doing so without affecting blood sugar levels, IGF-1 (the growth factor elevated by full-length growth hormone therapy), or insulin sensitivity. In preclinical studies, chronic treatment reduced body fat and increased fat oxidation in obese mice (Heffernan et al., International Journal of Obesity, 2001; Heffernan et al., Endocrinology, 2001). In the published human Phase IIa study (Stier et al., 2013), oral administration across dose groups confirmed that neither IGF-1 levels nor glucose and carbohydrate metabolism were meaningfully affected — the selective metabolic profile held in humans. However, the more clinically relevant Phase IIb efficacy trial, which tested subcutaneous injection in adults with obesity over 24 weeks, did not demonstrate statistically significant weight loss beyond placebo; those results remain in ASX corporate disclosures only and have not been independently peer-reviewed.

A separate line of investigation has examined AOD-9604 in the context of cartilage and joint repair. In a rabbit osteoarthritis model, intra-articular injection of AOD-9604 enhanced cartilage regeneration and outperformed hyaluronic acid alone (Kwon and colleagues, 2015). This is a single preclinical study; no human joint outcome data has been published.

Evidence

• Human: Phase IIa safety and tolerability study (METAOD004; Stier et al., 2013; n=36, oral dosing, 7 days) confirmed favorable safety and absence of IGF-1 or glucose effects. Phase IIb efficacy trial (Metabolic Pharmaceuticals, 2007; obese adults, ~300–500 subjects, subcutaneous injection, 24 weeks) did not meet its primary weight-loss endpoint versus placebo; results reported only in ASX corporate disclosures, not in peer-reviewed literature.
• Animal: Lipolysis, fat oxidation, and reduction of body fat accumulation demonstrated in obese mouse models and Zucker rats (Ng et al., 2000; Heffernan et al., 2001). A single rabbit osteoarthritis study showed intra-articular AOD-9604 enhanced cartilage regeneration and outperformed hyaluronic acid (Kwon et al., 2015).
• In vitro: Beta-3 adrenergic receptor activation and dose-dependent lipolysis in adipocyte models; proteoglycan synthesis stimulation in articular chondrocytes (supporting mechanistic basis for the cartilage-repair work).

Myths and misconceptions

• "AOD-9604 is a proven fat-loss peptide." — The Phase IIb obesity trial, the most rigorous human evaluation ever conducted on the molecule, did not meet its primary weight-loss endpoint versus placebo. Consumer and community marketing often leads with the original "lipolytic fragment" premise while omitting this central result. Some secondary outcomes in the trial were positive, but the clinical development program was discontinued and the drug was never approved.

• "AOD-9604 is FDA-approved because it has GRAS status." — GRAS is a food-safety designation under FDA food-ingredient regulations. It evaluates oral safety for consumption, not drug efficacy, and does not authorize marketing the compound as a treatment for obesity, joint disease, or any medical condition. These are separate regulatory pathways. AOD-9604 has never received FDA drug approval.

• "AOD-9604 gives you the fat-loss benefits of growth hormone without any of the side effects." — The published data do support that AOD-9604 does not meaningfully elevate IGF-1 or impair insulin sensitivity at studied doses — those are real differences from full-length GH. But the fat-loss effect of GH itself is modest and context-dependent, and the Phase IIb trial showed that isolating the lipolytic fragment did not translate into clinically meaningful weight reduction. Avoiding certain side effects of full GH is not the same as delivering the fat-loss benefit of full GH.

Known effects

• Selective lipolysis without IGF-1 elevation or hyperglycemia — Supported in human Phase I, IIa, and IIb trials. The mechanistic separation from full GH receptor signaling was the design intent and was confirmed across all trial phases.
• Clinically meaningful weight loss in obese adults — Contradicted. Phase IIb primary endpoint not met; obesity drug program discontinued.
• Cartilage regeneration — Preclinical only. Single rabbit OA study (Kwon et al., 2015); no human joint outcome data.
• Favorable short-term safety profile — Supported. No serious adverse events attributed to AOD-9604 across Phase I, IIa, and IIb studies (hundreds of subjects, up to 24 weeks); long-term safety beyond this window is not established.

Safety signals

Across the Phase I, IIa, and Phase IIb clinical program, AOD-9604 was generally well tolerated, with adverse events comparable to placebo in the described studies. Reported signals include mild injection-site reactions, transient headache, and mild flu-like symptoms at treatment initiation — all described as resolving without intervention. No serious adverse events were attributed to AOD-9604 in the published clinical program. No clinically significant effects on IGF-1, glucose tolerance, insulin sensitivity, or hypothalamic-pituitary-axis function were observed in human trials.

Published clinical exposure is limited to approximately 24 weeks. No chronic human safety surveillance data beyond this window is available in the literature. No human pregnancy, lactation, or pediatric safety data have been published.

Regulatory status

• US — FDA (drug): Not approved for any therapeutic indication. The Phase IIb obesity trial did not meet its primary endpoint; the drug development program was discontinued.
• US — FDA (food ingredient): Granted GRAS status as a food ingredient (FDA GRAS Notice No. 516; sources conflict on year: 2014 in one reference, 2021 in another — the discrepancy is unresolved). GRAS is a food-safety designation that does not evaluate efficacy or authorize therapeutic use marketing.
• US — compounding (503A): Excluded. The FDA Pharmacy Compounding Advisory Committee voted against inclusion of AOD-9604 in the 503A bulks list at its December 2024 meeting; it cannot be legally compounded by 503A pharmacies under this ruling.
• Australia — TGA: Not registered as a medicine. Sources note involvement with certain cartilage repair product filings; details are not fully resolved in available literature.
• EU / EMA: Not authorized as a medicine.
• UK — MHRA: Not licensed.
• Canada: Treated as an unapproved investigational agent.
• WADA: Prohibited at all times under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics), as a GH-derived fragment.

Mechanism

AOD-9604 activates beta-3 adrenergic receptors on the surface of adipocytes, triggering the hormone-sensitive lipase cascade that breaks down stored triglycerides into free fatty acids and glycerol. The same pathway also suppresses lipogenesis — the synthesis of new fat from surplus substrates. This dual effect on adipose tissue metabolism was demonstrated in cellular models, obese mouse studies, and Zucker rat models (Ng et al., 2000; Heffernan et al., 2001) and was reflected in secondary outcomes of the human clinical program, even where primary weight-loss endpoints were not met.

The critical mechanistic distinction from full-length GH is that AOD-9604 does not bind to the GH receptor and therefore does not stimulate IGF-1 production, promote tissue growth, induce insulin resistance, cause fluid retention, or suppress the hypothalamic-pituitary axis. This was confirmed in human trials across all phases. The beta-3 adrenergic mechanism is the proposed explanation for why AOD-9604 retained lipolytic activity in animal models without the broader systemic effects of GH.

In animal and cell-assay models, AOD-9604 has been shown to stimulate proteoglycan synthesis in articular chondrocytes — the proposed mechanistic basis for the cartilage and osteoarthritis work. This chondrocyte effect has not been validated in human joint tissue; it remains inferred from animal models and in vitro data.

The AOD-9604 translation failure in the Phase IIb obesity trial — robust preclinical evidence, negative clinical primary endpoint — is an unresolved question. Whether it reflects species differences in beta-3 adrenergic signaling density, dose selection, trial duration, or a fundamental gap in the mechanistic premise has not been answered in the literature.

Open questions

• Preclinical-to-clinical translation failure: Rodent and cell models showed robust lipolytic activity. The Phase IIb trial primary endpoint was not met. Whether this reflects species differences in beta-3 adrenergic signaling, dose selection, trial duration, population factors, or a fundamental mechanistic gap in humans remains unresolved.
• Cartilage repair in humans: No human joint outcome data has been published. The only animal evidence is a single rabbit osteoarthritis study (Kwon et al., 2015). The gap between rabbit cartilage and human clinical benefit is not bridged.
• Oral vs. subcutaneous pharmacokinetics: The only published human study (Stier et al., 2013) used oral dosing; the Phase IIb efficacy trial used subcutaneous injection. Rigorous human pharmacokinetic comparison of the two routes is not established.
• Long-term human safety: Clinical exposure in published trials is limited to approximately 24 weeks. Chronic-use human safety data beyond this window are not available.
• GRAS year discrepancy: Sources conflict on the year FDA granted GRAS status (GRAS Notice No. 516 cited as 2014 in one source and 2021 in another). Verification against the current FDA GRAS Notice Inventory is required.
• Sequence and molecular weight: Sources describe the peptide as either 16 or 17 amino acids, with the parent hGH boundary reported as 176–191 in some and 177–191 in others; molecular weight values also vary slightly across sources (1815 vs 1817 Da). The VDB entry for Ng et al. (2000) confirms 16 residues (YLRIVQCRSVEGSCGF) with the cyclic disulfide topology.
• Post-PCAC 2024 compounding landscape: The December 2024 PCAC vote against 503A inclusion changes the legal landscape for compounding access; downstream 503B pharmacy implications are not fully addressed in available literature.